Studies with the schistosomicide oxamniquine (UK-4271). II. Activity in primates.
D000284:Administration, Oral; D000351:Africa, Eastern; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002681:China; D004285:Dogs; D000882:Haplorhini; D007275:Injections, Intravenous; D007814:Larva; D007928:Lethal Dose 50; D008099:Liver / Q000382:microbiology; D008643:Mesentery / Q000382:microbiology; D009549:Nigeria; D009574:Nitro Compounds / Q000627:therapeutic use; D010215:Papio; D010270:Parasite Egg Count; D011437:Propylamines / Q000627:therapeutic use; D011647:Puerto Rico; D011804:Quinolines / Q000627:therapeutic use*; D011817:Rabbits; D012548:Schistosoma haematobium; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity
D000871:Anthelmintics; D009574:Nitro Compounds; D011437:Propylamines; D011804:Quinolines; D012556:Schistosomicides